Yksityisyysasetukset
Inderes käyttää evästeitä tarjotakseen paremman käyttökokemuksen ja henkilökohtaisemman palvelun. Hyväksymällä evästeiden käytön voimme kehittää palvelua entistä paremmin ja pystymme tarjoamaan sinua kiinnostavaa sisältöä.
  • Foorumi
  • Premium
  • Osakemarkkinat
    • PörssiReaaliaikaiset kurssit, indeksit ja markkinakehitys
    • AamukatsausPäivittäinen markkinakatsaus ja yön tärkeimmät tapahtumat
    • PörssikalenteriTulevat tulokset, listautumiset ja yritystapahtumat
    • OsinkokalenteriTulevat ja menneet osingot
  • Yhtiöt
    • YhtiötSelaa ja suodata listattujen yhtiöiden listaa
    • Löydä osakkeitaInspiraatiota seuraavaan sijoitukseesi
    • ListautumisetUudet listautumiset ja tulevat pörssiannit
    • YhtiökokouskutsutYhtiökokousten päivämäärät ja osakkeenomistajatiedot
  • Osaketutkimus
    • AnalyysiAsiantuntijoiden osakeanalyysi ja suositukset
    • ArtikkelitUutiset, näkemykset ja markkinakommentit
    • MallisalkkuInderesin mallisalkku
    • FemmeRohkeutta ja itseluottamusta sijoittamiseen
  • Opi sijoittamisesta
    • AnalyysikouluOpi lukemaan ja ymmärtämään osakeanalyysiä
    • SijoituskouluOppaita ja oppitunteja sijoitusosaamisen kasvattamiseen
    • SalkunhaltijatSijoitustietoa jokaiselle tasolle, ensiaskeleista edistyneisiin salkkustrategioihin.
    • inderesTVVideokeskus osaketutkimukselle, analyysille ja asiantuntijakommenteille
    • TranskriptitTulosjulkistusten ja sijoittajatapaamisten tekstimuotoiset tallenteet
    • OsakevertailuVertaa tunnuslukuja ja kehitystä useiden osakkeiden välillä
    • TuloskausiVertaile EPS-ennusteita toteutuneisiin tuloksiin
    • Sisäpiirin kaupatSeuraa yhtiöiden sisäpiiriläisten osto- ja myyntitoimintaa
    • LyhyeksimyyntiKatso, millä pörssiyhtiöillä on ilmoitettuja lyhyitä positioita
    • Virtuaalinen analyytikkochatEsitä kysymyksiä ja saa tekoälypohjaisia sijoitusnäkemyksiä
    • Korkoa korolle -laskuriLaske, miten säästösi kasvavat korkoa korolle -ilmiön ansiosta.
Sosiaalinen media
  • Inderes Foorumi
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Yhteystiedot
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Meistä
  • Tiimi
  • Avoimet työpaikat
  • Inderes sijoituskohteena
  • Palvelut pörssiyhtiöille
Sivusto
  • UKK
  • Q&A
  • Käyttöehdot
  • Tietosuojaseloste
  • Vastuuvapauslauseke

Inderesin vastuuvapauslauseke löytyy täältä. Kunkin Inderesin aktiivisessa seurannassa olevan osakkeen tarkemmat tiedot löytyvät kunkin osakkeen omilta yhtiösivuilta Inderes-sivustolla. © Inderes Oyj. Kaikki oikeudet pidätetään.

Transkriptit

Lue webcast- ja audiocast-lähetysten transkriptejä

Transkriptit

Lue webcast- ja audiocast-lähetysten transkriptejä

Kaikki markkinat
Suomi
Ruotsi
Tanska
Norja
Uusimmat
Suositut
Seuratut

Biotage, Audiocast, Q1'25

Julkaissut Inderes23.4.2025 klo 7.00
Biotage

Huomio: Tämä on koneellisesti luotu transkripti ja se saattaa sisältää epätarkkuuksia.

Frederic Vanderhaegen
00:00 - 03:05

Thank you. Good morning, everyone. Welcome to our Q1 report. Thank you for your flexibility today and for accommodating our recent time changes. Today's call is about the Q1 release. We will not comment on the recent announcements made by KKR. We would encourage anyone who has a question to reach out to Torben Jorgensen, who is our chairman of a subcommittee. That will address your questions going forward. Let me talk about our Q1 results. As expected, our Q1 revenue was softer than the prior year, primarily due to the volatility within our bioprocessing, which we had previously commented upon. Our relatively large exposure to the Plasmid preparation business has impacted our overall performance. However, we did see growth in our plasmid preparation revenue and bioprocessing. Gross margin continued to expand sequentially to reach 73.5%. We continue to build a strong foundation for future bioprocessing successes. Expanding our customer base. In this quarter, we added 37 new customers in the early phase of drug discovery, and over the past two years, we added more than 220 new customers. Our sales pipeline is strengthening, and we focus on partnering with our customers as they progress their modalities into late-stage development, which is going to be key as a leading indicator for future growth in the quarter. We took decisive actions to rightsize our bioprocessing cost base and drive strong integration, with the benefit of this starting to flow from quarter two onwards. This has been driven by a slowdown in our analytical testing activities, primarily due to a rationalization in one of our customer's operations and also some delay in purchasing decisions for systems coming mostly from the US. As a consequence of macroeconomic factors and recent announcements made by the Board. We were encouraged by the rebound in demand within the drug discovery segments, particularly in the North American area. We also saw growth in the Asia Pacific region, with China reporting quarter over quarter growth. Now, our demand continues to outstrip manufacturing capacity when it comes to our peptides. Had we been able to supply the peptide backlog, we would have been able to report mid-single digit growth in revenue for the core business. Our gross margin in the core business grew sequentially quarter over quarter and as regional, at 61.7%. Although we do recognize that the Q1 results are disappointing, we ourselves are not satisfied with them. We were pleased that March saw improvement momentum with mid-single-digit growth in consumable orders, which is very promising for onward revenue. We remain confident in our future mid to long-term outlook while managing the short-term headwinds with the right-sized cost base. Let me now turn it over to Andrew, who's going to walk you through more details on our financials. Thank you.

Andrew Kellett
03:06 - 09:22

Thank you, Fred. Good morning, everybody. The Q1 report, along with the presentation that's on the screen now, is available on the Biotage website under the investor section. And then financial reports. So in Q1, as Fred has just commented, our revenues were softer than Q1 2024, primarily due to the volatility within bioprocessing or large molecules, as we've previously flagged. Astrea has only a small number of customers who have products in the commercial stage, i.e., Released in the market. Fluctuations in demand from these customers can and do have a material impact on its revenue on a quarterly basis. Therefore, it has been repeatedly said that you cannot judge bioprocessing performance on a quarterly basis. As our business grows and matures, we see more of our early-stage customers' modalities moving into late-stage development and into production and commercialization. Our revenue concentration will ease and with it, our overall volatility. However, this is not measured in quarters, but rather in years. While we cannot say when and how fast those modalities will move through the pipeline, we are confident that the actions we are taking now will deliver the best chances of future success. Now our large molecules bioprocessing revenues were significantly down in Q1, as you've seen, due to lower plasmid preparation revenue in Q1 2025. We did not have any plasma revenue compared to approximately 90 million in Q1 2024. However, our Plasmid preparation revenue grew by 3% compared to Q1 2024. We did see growth of 3% in our small molecules revenue. Additionally, we saw growth in China of 16% in the quarter after a few years of consistent heavy declines, as we've noted in the Q1 report. We continued to see robust demand for our peptide systems, with demand outpacing manufacturing capacity, which has improved year on year. We experienced challenges in our analytical testing segment, with revenues declining by 8% year on year. This was driven by both specific macro factors and the rationalization of one of our customer's operations. We acquired 37 new customers in Q1. In early-stage research, we are adopting a much more rigorous approach to pipeline management, classifying our customers by clinical stage to give us better visibility of future revenue streams. Although we cannot predict when and if a customer will progress through the pipeline, the more customers we acquire and the more we partner with them in solving their problems, we increase our chances of future success. This, as Fred has always commented, is a numbers game requiring a medium-term outlook. While we are on this journey, we can still expect some significant short-term revenue volatility. As Fred has commented, our gross margins in the quarter were actually very strong on a group level. They were just under 63%, broadly on par with a very strong comparable Q1 2024 and up 1.1% sequentially on Q1, Q4 24. In bioprocessing, our Astrea business Q1 margins were 73.5%, up 7.87 points compared to Q1 2024 and 2.3 points sequentially. In the core quarter, one margins were 61.7%, up 5.1 points sequentially and just a small decline from a very strong comparable Q1 2024. Total operating costs in Q1 were $254 million, compared to $236 million in Q1 2024. However, when you adjust for one-off non-recurring costs, which were 22 million in Q1 versus 14 million in Q1 24, and the impact of effect translation costs, which we took an 8 million charge in Q1 versus a 5 million credit in Q1 2024. They were much higher in Q1 2025 due to significant swings in the FX rates in March, mainly centered around the US dollar. Then our adjusted OpEx at 224 million was actually lower than Q1 2024 of 227 million. So in Q1, we delivered an adjusted EBITDA of 50 million. This was weighed down by the softness in the bioprocessing revenue to mitigate this. We have taken decisive action to streamline our bioprocessing cost base and drive further integration. The benefits of this will start to flow from Q2 this year. In the quarter, we delivered adjusted cash flow from operations of 76 million, again down on the comparable quarter due to revenue softness. However, we continue to deliver adjusted cash flow from operations ahead of adjusted EBITDA. We finished the quarter with gross cash of 434 million and net cash of 182 million, on par with December 2024. To conclude, like Fredric said, we recognize that this quarter's results are disappointing, none more so than to us. However, we are very focused on putting in the building blocks for future growth. Undoubtedly, we're facing challenging headwinds, which will make 2025 quite a volatile year. But we remain confident that the actions we're executing now will put us in a good position for future success. Recognizing the executional as well as the market risks that lie ahead of us, we're now open to take any questions.

Operator
09:25 - 09:45

If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key on your telephone keypad. The next question comes from Matthias Hegbloom from Handelsbanken. Please go ahead.

Unknown 1
09:48 - 10:11

Good morning. Thanks so much for taking my question. I have. First, a clarification. So, um, you stated in the report that if you had been able to deliver at the demand for Peptide Systems, it would have translated into mid-single digit growth. It's not clear to me if that was for the Biotage group or only for Biotage. If it references the group, it's a delta. Yeah, please.

Andrew Kellett
10:11 - 10:14

It's. No, it's for the core business.

Unknown 1
10:16 - 10:33

Okay. And I'm not sure I saw that in the report, but could you remind me what the organic growth for core was? So we can back out and understand the magnitude? Or if you can help me, then. In absolute terms, how large would the backlog be, which I guess is what we're trying to determine here.

Andrew Kellett
10:34 - 10:45

Well, if you think about it, we kind of consider the backlog to be just under approximately 20 million SEK for peptide systems.

Unknown 1
10:46 - 10:58

Yep. That's helpful. And, um, remind me, what alternatives do customers have when you can't deliver? And secondly, tied to that, when do you expect to be able to produce to meet demand?

Frederic Vanderhaegen
11:00 - 11:57

Yes. So yes, we are working with the third-party providers. So I think there are two impacts. First, we can't recognize revenue. Obviously. The second one is our lead time is substantial relative to the demand. So, uh, if we look into the second part, we are clearly recognizing that we're missing opportunities in the market. Uh, since customers are looking to expand their peptide purification. So, uh, our mitigation plan has been to work with our third-party providers to unleash the potential from access to the parts. That is the first step, and we are working with them to resume the output that we had last year in Q3 and Q4. But that's the maximum we can get to. So, I think we have to look for alternative paths to accelerate our market reach there, which we're exploring right now.

Unknown 1
12:00 - 12:26

That's helpful. Two more questions, please. So on slide seven with customer numbers for Astrea, it's a nice contribution to help the outside world understand the nature of your business. Unfortunately, that may be the only time we'll get to see it as well. But I wanted to understand the math here better. New customers? Is that a net number of won and lost during the year, or has that actually not lost a single customer since 2022?

Andrew Kellett
12:28 - 12:45

Um, it is a net number. But effectively, we're not losing customers. You know, the number of lost customers. I can't think of any really off the top of my head. So effectively, those are the new customers. We're winning. The level of losses is negligible.

Unknown 1
12:48 - 13:08

That's clear. And my final point is still on slide seven. Great. With the breakdown of customers per stage, but only referencing the commercial stage and more or less all columns and fiber in the preclinical stage. Can you help me understand the revenue split between reference columns and fiber? The vast majority of revenues come from reference, then. Or how should we think about that breakdown?

Andrew Kellett
13:10 - 13:38

So, in that, the majority of you can broadly think about fiber, which obviously is a new technology. The revenue from that is very small, almost negligible from an Astrea perspective. Um, and you can think of the resin column split broadly as about 85 to 90% in resins and 10 to 15% in columns.

Unknown 1
13:40 - 13:43

Very helpful. Thanks so much. Thank you.

Operator
13:51 - 14:19

As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.

Frederic Vanderhaegen
14:20 - 15:35

So thank you. Uh, operator. So thank you to those of you who have joined this call. So we, uh, we again, want to reiterate that we are not commenting on the announcements, and we want to encourage any of you who have questions about that topic to reach out to, uh, Torben Jorgensen, who is acting as a representative of the board, or to reach out to KKR. So, as we said, we recognize that Q1 was a challenging quarter for us, mostly driven by the situation that we had in our bioprocessing space. We entered the year with a very weak backlog, but we are committed and working on expanding our customer base and addressing the opportunities, bridging the short-term revenue gap with our packing column strategies out of our Canton site that is now commissioned and operational, which will help us accelerate our momentum onwards. And in the meantime, we continue driving our drug discovery process as well as our applied market. As an organization, we have built new strategic vectors to proceed forward, and we'll be happy to share those with you as we progress onwards on the journey. Thank you all for joining us today and we look forward to speaking to you next quarter.

Katso webcast
Revenio Group Oyj, Q3'26
Kieli: englanti12.11.2026 klo 13.00
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Kieli: englanti12.11.2026 klo 9.00
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Kieli: suomi12.11.2026 klo 8.00
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Kieli: suomi11.11.2026 klo 9.00
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Kieli: englanti10.11.2026 klo 11.00
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Kieli: suomi10.11.2026 klo 10.00
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Kieli: englanti10.11.2026 klo 9.00
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Kieli: englanti9.11.2026 klo 12.00
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Kieli: englanti6.11.2026 klo 12.30
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 13.00
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Kieli: englanti5.11.2026 klo 11.00
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 10.30
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Kieli: englanti5.11.2026 klo 10.00
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 9.00
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Kieli: englanti5.11.2026 klo 8.30
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 8.00
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Kieli: englanti5.11.2026 klo 7.30
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Kieli: englanti4.11.2026 klo 12.00
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Kieli: suomi4.11.2026 klo 9.00
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Kieli: englanti4.11.2026 klo 8.30
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…